Filtered By:
Drug: Angiomax

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 71 results found since Jan 2013.

Effectiveness and Safety of Bivalirudin During Percutaneous Coronary Intervention in Acute Coronary Syndrome in the Real World: CARTAGOMAX Study
Abstract: The CARTAGOMAX study assessed the safety and efficacy of bivalirudin during real-world cardiac intervention. This was a single-center prospective study. Patients with acute coronary syndrome undergoing percutaneous coronary intervention were anticoagulated with bivalirudin alone or unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor. Propensity score matching was performed to control for baseline imbalances and yielded 1168 patients. There was lower incidence of the composite outcome of death from any cause or major bleeding at 30 days (P = 0.005), 6 months (P = 0.005), and 12 months (P = 0.001) of foll...
Source: Journal of Cardiovascular Pharmacology - September 1, 2016 Category: Cardiology Tags: Original Article Source Type: research

Hemorrhagic and ischemic outcomes of Heparin vs. Bivalirudin in carotid artery stenting: A meta ‐analysis of studies
ConclusionCompared to UFH, Bivalirudin is associated with lower bleeding risk when used during CAS. © 2016 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - August 15, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Jad Omran, Obai Abdullah, Mazen Abu ‐Fadel, William A Gray, Belal Firwana, Douglas E Drachman, Ehtisham Mahmud, Herebert D Aronow, Christopher J White, Ashraf S Al‐Dadah Tags: Peripheral Vascular Disease Source Type: research

Cerebral Embolism During Transcatheter  Aortic Valve Replacement The BRAVO-3 MRI Study
ConclusionsThis study documented cerebral embolization in nearly two-thirds of patients during contemporary TAVR. There were no significant differences in cerebral embolization for bivalirudin versus heparin anticoagulation during TAVR. (Open-Label, Randomized Trial in Patients Undergoing TAVR to Determine Safety and Efficacy of Bivalrudin vs. UFH [BRAVO-2/3]; NCT01651780)
Source: Journal of the American College of Cardiology - August 2, 2016 Category: Cardiology Source Type: research

Sex ‐Based Differences In Outcomes With Bivalirudin Or Unfractionated Heparin For Transcatheter Aortic Valve Replacement: Results From The BRAVO 3 Randomized Trial
Conclusions: There was no difference in early outcomes with bivalirudin versus UFH in men or women undergoing contemporary TAVR. This article is protected by copyright. All rights reserved.
Source: Catheterization and Cardiovascular Interventions - June 30, 2016 Category: Cardiovascular & Thoracic Surgery Authors: A Asgar, J Chandrasekhar, G Mikhail, J Webb, T Lefevre, C Tamburino, D Hildick ‐Smith, R Hambrecht, E Van Belle, J Widder, N Dumonteil, U Hink, R Jeger, A Linke, E Dellargyris, P Gao, R Mehran, C Hengstenberg, P Anthopoulos, G Dangas, Tags: Original Studies Source Type: research

Sex‐Based Differences In Outcomes With Bivalirudin Or Unfractionated Heparin For Transcatheter Aortic Valve Replacement: Results From The BRAVO 3 Randomized Trial
Conclusions: There was no difference in early outcomes with bivalirudin versus UFH in men or women undergoing contemporary TAVR. This article is protected by copyright. All rights reserved.
Source: Catheterization and Cardiovascular Interventions - April 30, 2016 Category: Cardiovascular & Thoracic Surgery Authors: A Asgar, J Chandrasekhar, G Mikhail, J Webb, T Lefevre, C Tamburino, D Hildick‐Smith, R Hambrecht, E Van Belle, J Widder, N Dumonteil, U Hink, R Jeger, A Linke, E Dellargyris, P Gao, R Mehran, C Hengstenberg, P Anthopoulos, G Dangas, Tags: Original Studies Source Type: research

Bivalirudin Is Associated With Improved In-Hospital Outcomes Compared With Heparin in Percutaneous Vascular Interventions: Observational, Propensity-Matched Analysis From the Premier Hospital Database Peripheral Vascular Disease
Conclusions— In patients undergoing peripheral vascular interventions, procedural anticoagulation with bivalirudin may result in more favorable in-hospital outcomes compared with unfractionated heparin, the current standard of care. These observations will require prospective confirmation in a randomized, controlled trial.
Source: Circulation: Cardiovascular Interventions - January 8, 2016 Category: Cardiology Authors: Kimmelstiel, C., Pinto, D., Aronow, H. D., Weintraub, A. R., Dangas, G., Fan, W., Prats, J., Deliargyris, E. N., Katzen, B. T. Tags: Anticoagulants, Pharmacology, Peripheral Vascular Disease, Vascular Disease Source Type: research

Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement The Randomized BRAVO-3 Trial
BackgroundAnticoagulation is required during transcatheter aortic valve replacement (TAVR) procedures. Although an optimal regimen has not been determined, heparin is mainly used. Direct thrombin inhibition with bivalirudin may be an effective alternative to heparin as the procedural anticoagulant agent in this setting.ObjectivesThe goal of this study was to determine whether bivalirudin offers an alternative to heparin as the procedural anticoagulant agent in patients undergoing TAVR.MethodsA total of 802 patients with aortic stenosis were randomized to undergo transfemoral TAVR with bivalirudin versus unfractionated hepa...
Source: Journal of the American College of Cardiology - December 21, 2015 Category: Cardiology Source Type: research

Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial
Publication date: Available online 5 November 2015 Source:The Lancet Author(s): A Michael Lincoff, Roxana Mehran, Thomas J Povsic, Steven L Zelenkofske, Zhen Huang, Paul W Armstrong, P Gabriel Steg, Christoph Bode, Mauricio G Cohen, Christopher Buller, Peep Laanmets, Marco Valgimigli, Toomas Marandi, Viliam Fridrich, Warren J Cantor, Bela Merkely, Jose Lopez-Sendon, Jan H Cornel, Jaroslaw D Kasprzak, Michael Aschermann, Victor Guetta, Joao Morais, Peter R Sinnaeve, Kurt Huber, Rod Stables, Mary Ann Sellers, Marilyn Borgman, Lauren Glenn, Arnold I Levinson, Renato D Lopes, Vic Hasselblad, Ri...
Source: The Lancet - November 6, 2015 Category: Journals (General) Source Type: research

TCT: Structural Heart Disease and PFO Closure TrialsTCT: Structural Heart Disease and PFO Closure Trials
Drs Harrington and Bhatt discuss whether transcatheter aortic valve therapy is evolving naturally or moving beyond the evidence, bivalirudin in TAVR, and PFO closure for stroke prevention. theheart.org on Medscape
Source: theHeart.org - October 19, 2015 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Impact of Arterial Access Site on Outcomes After Primary Percutaneous Coronary Intervention: Prespecified Subgroup Analysis From the EUROMAX Trial Coronary Interventions
Conclusions— In this prespecified analysis from EUROMAX, radial access was preferred in lower risk patients and did not improve clinical outcomes. Bivalirudin was associated with less bleeding irrespective of access site. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01087723.
Source: Circulation: Cardiovascular Interventions - June 8, 2015 Category: Cardiology Authors: Hamon, M., Coste, P., van't Hof, A., Ten Berg, J., Clemmensen, P., Tabone, X., Benamer, H., Kristensen, S. D., Cavallini, C., Marzocchi, A., Hamm, C., Kanic, V., Bernstein, D., Anthopoulos, P., Deliargyris, E. N., Steg, P. G. Tags: Cardiovascular Pharmacology, Catheter-based coronary and valvular interventions: other, Acute myocardial infarction Coronary Interventions Source Type: research

Trial of bivalirudin during angioplasty reports mixed results
(American College of Cardiology) Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints -- a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding -- as compared to patients receiving standard anticoagulation therapy, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session.
Source: EurekAlert! - Medicine and Health - March 16, 2015 Category: Global & Universal Source Type: news

Bivalirudin vs Heparin With or Without Tirofiban During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction The BRIGHT Randomized Clinical Trial
ImportanceThe safety and efficacy of bivalirudin compared with heparin with or without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI) are uncertain.ObjectiveTo determine if bivalirudin is superior to heparin alone and to heparin plus tirofiban during primary PCI.Design, Setting, and ParticipantsMulticenter, open-label trial involving 2194 patients with AMI undergoing primary PCI at 82 centers in China between August 2012 and June 2013.InterventionsPatients were randomly assigned to receive bivalirudin with a post-PCI infusion (...
Source: JAMA - Journal of the American Medical Association - March 16, 2015 Category: Journals (General) Source Type: research

Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention Pooled Patient-Level Analysis From the HORIZONS-AMI and EUROMAX Trials
BackgroundIn the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial, 3,602 patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) treated with bivalirudin had lower bleeding and mortality rates, but higher acute stent thrombosis rates compared with heparin + a glycoprotein IIb/IIIa inhibitor (GPI). Subsequent changes in primary PCI, including the use of potent P2Y12 inhibitors, frequent radial intervention, and pre-hospital medication administration, were incorporated into the EUROMAX (European Ambu...
Source: Journal of the American College of Cardiology - January 5, 2015 Category: Cardiology Source Type: research

A regional pharmacoinvasive PCI strategy incorporating selected bleeding avoidance strategies
ConclusionBleeding and ischemia rates were similar between the PIT and primary PCI strategies in the setting of routine use of selected BAS; further study on a broader range of BAS including the radial approach may be warranted. Cardiac arrest and bailout glycoprotein IIb/IIIa inhibitor, but not PIT in conjunction with selected BAS, are independent predictors of bleeding risk in a regional ST-segment elevation myocardial infarction population.
Source: Coronary Artery Disease - December 10, 2014 Category: Cardiology Tags: Original Research Source Type: research

Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program
Publication date: December 2014 Source:American Heart Journal, Volume 168, Issue 6 Author(s): Marco Valgimigli Background Transradial intervention (TRI) and bivalirudin infusion compared with transfemoral coronary intervention or unfractionated heparin plus glycoprotein IIb/IIIa inhibitors decrease bleeding complications in patients with acute coronary syndromes (ACS). Although bleeding is thought to be associated with worse outcomes, it remains unclear whether TRI and bivalirudin both independently lower ischemic or combined ischemic and bleeding complications in ACS patients undergoing contemporary invasive management....
Source: American Heart Journal - November 25, 2014 Category: Cardiology Source Type: research